Vanda Pharmaceuticals Inc (VNDA) financials
Vanda Pharmaceuticals revenue and earnings by year
Vanda Pharmaceuticals's revenue was $216 million in the fiscal year to December 31, 2025, up 8.7% from the year before. Net income was -$220 million, -102.0% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 4.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216 | 199 | 193 | 254 | 269 | 248 | 227 | 193 | 165 | 146 |
| Revenue growth | 8.7% | 3.2% | -24.3% | -5.3% | 8.3% | 9.2% | 17.6% | 17.0% | 13.1% | — |
| Gross profit | 203 | 187 | 178 | 230 | 243 | 225 | 203 | 173 | 147 | 121 |
| Gross margin | 94.0% | 94.3% | 92.3% | 90.5% | 90.5% | 90.6% | 89.2% | 89.4% | 89.2% | 83.1% |
| Operating income | -151 | -41 | -14 | 6 | 42 | 27 | 23 | 22 | -17 | -19 |
| Operating margin | -70.0% | -20.5% | -7.2% | 2.5% | 15.7% | 11.0% | 10.0% | 11.3% | -10.2% | -12.7% |
| Net income | -220 | -19 | 3 | 6 | 33 | 23 | 116 | 25 | -16 | -18 |
| Net margin | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% | 9.4% | 50.9% | 13.1% | -9.4% | -12.3% |
| Diluted EPS | -$3.74 | -$0.33 | $0.04 | $0.11 | $0.58 | $0.43 | $2.12 | $0.47 | -$0.35 | — |
| Free cash flow | -110 | -16 | 12 | 31 | 64 | 50 | 45 | 5 | -4 | -10 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open VNDA in Markets.
How Vanda Pharmaceuticals makes money
Revenue by segment in the quarter to September 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Fanapt | $38.8M | 55.5% |
| Hetlioz | $21.7M | 31.1% |
| PONVORY | $7.75M | 11.1% |
| NEREUS | $1.61M | 2.3% |
See also: VNDA valuation and P/E history · VNDA returns
No forecast, no recommendation. This page describes Vanda Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.